As tissue eosinophil numbers were not increased in stable‐state T2‐high severe asthma, the efficacy of anti‐IL5/IL‐5Rα and anti‐IL‐4Rα therapy on exacerbations may be due to their effects on systemic rather than tissue eosinophils, preventing recruitment and further trafficking to the tissue during exacerbations. The gene discussed is IL4R; the disease is asthma.